These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Mendelman PM; Rappaport R; Cho I; Block S; Gruber W; August M; Dawson D; Cordova J; Kemble G; Mahmood K; Palladino G; Lee MS; Razmpour A; Stoddard J; Forrest BD Pediatr Infect Dis J; 2004 Nov; 23(11):1053-5. PubMed ID: 15545863 [TBL] [Abstract][Full Text] [Related]
4. Antibody responses to inactivated influenza vaccines and partial protective effect of anti-neuraminidase antibody against epidemics of A(H3N2) and A(H1N1) influenza. Maeda A; Oishi I; Minekawa Y; Kunita N; Funahashi S; Yagura H Biken J; 1979 Sep; 22(3):91-8. PubMed ID: 533537 [No Abstract] [Full Text] [Related]
5. The response to inactivated influenza A (H3N2) vaccines: the development and effect of antibodies to the surface antigens. Smith AF; Davies JR J Hyg (Lond); 1977 Jun; 78(3):363-75. PubMed ID: 266540 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. Sugaya N; Nerome K; Ishida M; Matsumoto M; Mitamura K; Nirasawa M JAMA; 1994 Oct; 272(14):1122-6. PubMed ID: 7933325 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of influenza vaccine in the elderly: reduction in risks of mortality and morbidity during an influenza A (H3N2) epidemic for the elderly in nursing homes. Deguchi Y; Takasugi Y Int J Clin Lab Res; 2000; 30(1):1-4. PubMed ID: 10984124 [TBL] [Abstract][Full Text] [Related]
8. [Characteristics of the immune response in children multiply inoculated with an inactivated influenza vaccine]. Rudenko LG; Vasil'eva RI; Smirnova LA; Doroshenko EM Vopr Virusol; 1988; 33(4):407-11. PubMed ID: 3195142 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of inactivated influenza vaccine containing A/Niigata/102/81 (H3N2). Increase of HAI antibodies to different variants of the subtype. Takeuchi Y; Takahashi M; Satsuta K; Hatta S; Suzuki H; Ogawa Y; Hirano S; Takahashi K; Yamazi Y Nihon Ika Daigaku Zasshi; 1985 Oct; 52(5):607-10. PubMed ID: 4066903 [No Abstract] [Full Text] [Related]
10. [The evaluation of the efficacy of repeated inoculations against influenza using inactivated vaccines]. Avratinskiĭ IM; Stepankovskaia LD; Katuntsevskaia GP; Kiriliuk ZhI; Kalitsev VA; Iampol'skiĭ MP; Burdeniuk EI Lik Sprava; 1992 Mar; (3):79-81. PubMed ID: 1413699 [No Abstract] [Full Text] [Related]
11. [Postvaccinal anti-influenza immunity and its determining factors]. Kastrikina LN; Lonskaia NI Vopr Virusol; 1990; 35(5):362-7. PubMed ID: 2267774 [No Abstract] [Full Text] [Related]
12. Recommended composition of influenza virus vaccines for use in the 2007-2008 influenza season. Wkly Epidemiol Rec; 2007 Mar; 82(9):69-74. PubMed ID: 17333570 [No Abstract] [Full Text] [Related]
13. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410 [TBL] [Abstract][Full Text] [Related]
14. Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season. Wkly Epidemiol Rec; 2011 Mar; 86(10):86-90. PubMed ID: 21395187 [No Abstract] [Full Text] [Related]
15. Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season. Wkly Epidemiol Rec; 2012 Mar; 87(10):83-95. PubMed ID: 22462202 [No Abstract] [Full Text] [Related]
16. [The evaluation of the epidemiological efficacy of 3-component inactivated influenza vaccines using an intranasal application method]. Marinich IG; Iaroshevskaia IIu; Konareva AL; Lonskaia NI; Shadrin AS; Salmin LV Zh Mikrobiol Epidemiol Immunobiol; 1993; (6):76-8. PubMed ID: 8079581 [No Abstract] [Full Text] [Related]
17. Recommended composition of influenza virus vaccines for use in the 2013 southern hemisphere influenza season. Wkly Epidemiol Rec; 2012 Oct; 87(41):389-400. PubMed ID: 23074737 [No Abstract] [Full Text] [Related]
18. Recommended composition of influenza virus vaccines for use in the 2016 southern hemisphere influenza season. Wkly Epidemiol Rec; 2015 Oct; 90(41):545-59. PubMed ID: 26454888 [No Abstract] [Full Text] [Related]
19. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. Wkly Epidemiol Rec; 2014 Mar; 89(10):93-104. PubMed ID: 24707514 [No Abstract] [Full Text] [Related]
20. [Antibody formation and preservation against the envelope antigens of influenza virus subtype A(H3N2) after infection and vaccination]. Stumpa A; Tůmová B Tr Inst Im Pastera; 1982; 59():23-8. PubMed ID: 6764986 [No Abstract] [Full Text] [Related] [Next] [New Search]